Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | +11.95% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.70 | N/A | +11.95% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions but remains focused on long-term goals. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Nektar Therapeutics reported a wider-than-expected loss per share, which contributed to a 2.17% drop in stock price. The lack of revenue details and guidance updates left investors uncertain about the company's future performance. Management's cautious tone suggests they are navigating significant challenges ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021